Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
AFT Leaves X Over AI-Generated Images of Minors 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
 & Lead Plaintiff Deadline: May 8, 2017 - EconoTimes)
NEW YORK, March 30, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against NantHealth, Inc. (“NantHealth” or the “Company”) (NASDAQ:NH) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased NantHealth securities (1) pursuant and/or traceable to NantHealth’s false and misleading Registration Statement and Prospectus, issued in connection with the Company’s initial public offering on or about June 2, 2016 (the “IPO” or the “Offering”); and/or (2) on the open market between June 2, 2016 and March 3, 2017, both dates inclusive (the “Class Period”). Investors are encouraged to learn more about this case by visiting the firm’s site: http://www.bgandg.com/nh.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
In September 2014, NantHealth’s founder and Chief Executive Officer (“CEO”), Defendant Patrick Soon-Shiong, publicized a $12 million donation to the University of Utah for an initiative to find genetic clues for the cause of diseases, including several cancers and amyotrophic lateral sclerosis. The donation came from three different tax-exempt entities controlled by Soon-Shiong: $9 million from two private foundations, and the remaining $3 million from the NantHealth Foundation, a medical research organization.
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Defendant Soon-Shiong focused business to NantHealth through his donation to the University of Utah, pursuant to the contractual terms of which the university was effectively required to spend $10 million on genetics analysis performed by the Company; (2) as a result, the number of test orders that NantHealth reported to investors was artificially inflated; (3) the contracts governing Soon-Shiong’s donation to the university violated federal tax law; and (4) consequently, NantHealth’s public statements were materially false and misleading at all relevant times.
On March 6, 2017, STAT, a news source, reported that NantHealth founder, Patrick Soon-Shiong, had donated $12 million to the University of Utah from three different tax-exempt entities he controlled under a contract that required the University to funnel most of that money into NantHealth. STAT also alleged that this scheme allowed NantHealth to inflate the number of test orders it reported to investors. Following this news, NantHealth stock dropped $1.67 per share, or 23.29%, to close at $5.50 on March 6, 2017.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/nh or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. You have until May 8, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
